Equities analysts expect Insulet Co. (NASDAQ:PODD) to post $0.12 earnings per share for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Insulet’s earnings, with the lowest EPS estimate coming in at $0.05 and the highest estimate coming in at $0.23. Insulet posted earnings of $0.22 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 45.5%. The business is expected to announce its next quarterly earnings results on Thursday, August 5th.
According to Zacks, analysts expect that Insulet will report full-year earnings of $0.77 per share for the current year, with EPS estimates ranging from $0.51 to $1.14. For the next year, analysts expect that the firm will post earnings of $1.55 per share, with EPS estimates ranging from $0.95 to $2.15. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Insulet.
Insulet (NASDAQ:PODD) last posted its earnings results on Monday, February 22nd. The medical instruments supplier reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.22). Insulet had a return on equity of 8.94% and a net margin of 3.33%. The business had revenue of $246.10 million for the quarter, compared to the consensus estimate of $232.89 million. During the same period in the previous year, the company posted $0.08 earnings per share. Insulet’s revenue for the quarter was up 17.5% compared to the same quarter last year.
NASDAQ PODD traded down $4.32 during trading hours on Wednesday, reaching $225.64. 35,836 shares of the company’s stock were exchanged, compared to its average volume of 497,792. The company’s 50-day moving average is $276.80 and its two-hundred day moving average is $264.28. Insulet has a one year low of $164.40 and a one year high of $306.46. The company has a debt-to-equity ratio of 1.55, a quick ratio of 5.91 and a current ratio of 6.62. The company has a market capitalization of $14.94 billion, a price-to-earnings ratio of 514.31 and a beta of 0.76.
In other Insulet news, CEO Shacey Petrovic sold 15,000 shares of the stock in a transaction that occurred on Thursday, April 1st. The shares were sold at an average price of $266.17, for a total transaction of $3,992,550.00. Following the transaction, the chief executive officer now owns 56,589 shares in the company, valued at approximately $15,062,294.13. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.10% of the company’s stock.
Several large investors have recently made changes to their positions in the business. Janus Henderson Group PLC grew its position in shares of Insulet by 31.4% during the 4th quarter. Janus Henderson Group PLC now owns 719,062 shares of the medical instruments supplier’s stock worth $183,814,000 after purchasing an additional 171,770 shares in the last quarter. Lord Abbett & CO. LLC grew its position in shares of Insulet by 40.4% during the 1st quarter. Lord Abbett & CO. LLC now owns 523,587 shares of the medical instruments supplier’s stock worth $136,614,000 after purchasing an additional 150,748 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Insulet by 3.2% during the 4th quarter. Bank of New York Mellon Corp now owns 518,840 shares of the medical instruments supplier’s stock worth $132,631,000 after purchasing an additional 16,117 shares in the last quarter. Norges Bank acquired a new position in shares of Insulet during the 4th quarter worth approximately $128,482,000. Finally, Viking Global Investors LP grew its position in shares of Insulet by 125.6% during the 4th quarter. Viking Global Investors LP now owns 483,529 shares of the medical instruments supplier’s stock worth $123,605,000 after purchasing an additional 269,197 shares in the last quarter.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager.
Further Reading: What is a Backdoor Roth IRA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.